Palvella Therapeutics announced FDA acceptance and Priority Review for its rapamycin NDA, with a PDUFA date set for February 2027. The breakthrough therapy designation and strong Phase 3 efficacy results suggest a potential first-in-market approval for rare vascular anomalies.